Cargando…

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat

CASE SUMMARY: A 14-year-old, domestic shorthair cat was treated for transient diabetes mellitus for 3 months with glargine insulin, which was discontinued when the diabetes mellitus resolved. Approximately 36 months later the diabetes mellitus recurred and glargine insulin was restarted. Within 2–3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murphy, Lisa A, Zuendt, Greg F, Nakamura, Reid K, Gambardella, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362920/ https://www.ncbi.nlm.nih.gov/pubmed/28491437 http://dx.doi.org/10.1177/2055116916668892

Ejemplares similares

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes
por: Lucidi, Paola, et al.
Publicado: (2012)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2012)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Hypersensitivity reaction associated with phenytoin
por: Indu, T. H., et al.
Publicado: (2015)

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
por: GAO, GUAN-QI, et al.
Publicado: (2014)

Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats
por: Uehata, Keiko, et al.
Publicado: (2011)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients
por: Bhurayanontachai, Rungsun, et al.
Publicado: (2018)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Lumbosacral agenesis in a cat
por: Hybki, Gabrielle C, et al.
Publicado: (2016)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis
por: Endall, Ryan, et al.
Publicado: (2020)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

Subcutaneous extraskeletal chondroblastic osteosarcoma in a cat
por: Verdes, José Manuel, et al.
Publicado: (2019)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Insulin Glargine Safety in Pregnancy: A transplacental transfer study
por: Pollex, Erika K., et al.
Publicado: (2010)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Insulin glargine use and breast cancer risk: Associations with cumulative exposure
por: Peeters, Paul J. H. L., et al.
Publicado: (2016)

Cutaneous Metal Hypersensitivity Reaction
por: Yang, Sun, et al.
Publicado: (2022)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
por: Lin, Shuo, et al.
Publicado: (2018)

How much is too much? Outcomes in patients using high‐dose insulin glargine
por: Reid, T., et al.
Publicado: (2015)

Exogenous recombinant human insulin-induced severe hypersensitivity reaction precipitating hyperglycemic crisis: A clinical conundrum
por: Lijesh, KU, et al.
Publicado: (2020)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

A persistent dermal hypersensitivity reaction associated with Helicobacter pylori infection
por: Dautriche, Cula N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tqtfi1bfrlvrn9ek7qg6orkjgp